Business
NFL Biosciences Strengthens Its Cash Position by €2.6 Million Through Bond Financing Subscribed by a Group of European Institutional Investors
MONTPELLIER, France, April 15, 2026--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today announces the extension of its cash runway until the third quarter of 2027 through new financing.
About this update from Nfl Biosciences Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"A €2.6 million bond financing has been secured with a group of European investors including Vester Finance, a shareholder of the Company","length":136,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash runway is immediately extended until the third quarter of 2027","length":67,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":203,"olType":false},{"type":"text","content":"MONTPELLIER, France, April 15, 2026--(BUSINESS WIRE)--Regulatory News:","length":70,"tagName":"p"},{"type":"text","content":"NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today announces the extension of its cash runway until the third quarter of 2027 through new financing.","length":266,"tagName":"p"},{"type":"text","content":"Bruno Lafont, Chief Executive Officer and co-founder of NFL Biosciences, states: "We would like to thank the investors for their confidence and participation in this transaction, and especially Vester Finance, a long-standing partner of the Company, for its continued support. This financing strengthens our cash visibility and enables us to reach a key milestone in the development of NFL-102. The funds raised will be used to finance the TONIC Phase 2 study, the aim of which is to confirm the safety of NFL-102, assess its efficacy and determine the optimal dose. NFL-102 is based on a novel mechanism of action targeting the deep neuronal mechanisms underlying tobacco and nicotine addiction."","length":707,"tagName":"p"},{"type":"text","content":"Main characteristics of the bond issues","length":39,"tagName":"p"},{"type":"text","content":"The issuance of the convertible bonds was decided by the Board of Directors on April 15, 2026, acting pursuant to the delegation granted to it by the Company’s shareholders’ general meeting of May 21, 2025 (the "General Meeting")1 under its 11th resolution.","length":267,"tagName":"p"},{"type":"text","content":"The convertible bonds, with a nominal value of €10 each, were subscribed at 92% of their nominal value, corresponding to a total subscription price of €2,392,000.00, paid in full on the subscription date. They will bear no interest and will not benefit from any security. They may be converted ...